A Delayed Inoculation Model of Chronic Pseudomonas aeruginosa Wound Infection
February 20th, 2020
8.2K views
We describe a delayed inoculation protocol for generating chronic wound infections in immunocompetent mice.
Overview
This article describes a delayed inoculation protocol for generating chronic wound infections in immunocompetent mice. The model focuses on chronic Pseudomonas aeruginosa wound infection without foreign material implantation or immune suppression.
Key Study Components
Area of Science
- Microbiology
- Infectious Diseases
- Animal Models
Background
- Chronic infections pose significant challenges in treatment.
- Pseudomonas aeruginosa is a common pathogen in wound infections.
- Existing models often require foreign materials or immune suppression.
- This study aims to establish a new model for chronic infection research.
Purpose of Study
- To develop a model for studying chronic Pseudomonas aeruginosa infections.
- To investigate bacterial pathogenesis and host-pathogen interactions.
- To aid in the development of new therapies for chronic infections.
Methods Used
- Delayed inoculation of Pseudomonas aeruginosa 24 hours post-wounding.
- Use of full thickness excisional wounds in mice.
- Monitoring infection duration lasting seven to ten days.
- Involvement of medical students in procedural demonstrations.
Main Results
- Successful establishment of chronic infections without immune suppression.
- Infection model allows for detailed study of bacterial behavior.
- Demonstrated the feasibility of the protocol in immunocompetent mice.
- Potential for application in therapeutic development.
Conclusions
- This model provides a valuable tool for chronic infection research.
- It facilitates the study of host-pathogen interactions.
- The protocol can lead to advancements in treatment strategies for chronic wounds.
Frequently Asked Questions
What is the significance of this protocol?
It establishes a model for chronic Pseudomonas aeruginosa infections without immune suppression.
How long does the infection last?
The infection lasts approximately seven to ten days.
What type of mice are used in this study?
Immunocompetent mice aged eight to twelve weeks are used.
What is the role of Dan Liu in this study?
Dan Liu assists in demonstrating the procedure as a medical student.
What are the implications of this research?
It aids in understanding chronic infections and developing new therapies.
Is foreign material required for this model?
No, the model does not require foreign material implantation.
Executive Industry Relevance
This delayed inoculation model addresses a critical gap in preclinical wound infection research by enabling chronic Pseudomonas aeruginosa studies without foreign body implantation or immunosuppression. The model supports mechanistic de-risking of anti-infective candidates by replicating the temporal dynamics of post-operative wound infections in humans. Quantitative bioluminescence readouts provide predictive confidence for target validation and lead optimization in antimicrobial development programs.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses in a clinically relevant chronic infection context.
- Operational Value: Supports functional target validation through sustained pathogen presence over 7–10 days.
- Predictive Value: Facilitates portfolio triage by modeling bacterial persistence without artificial infection prolongation methods.
Screening & Assay Development
- Assay Readiness: Generates standardized, reproducible wound infection models for compound screening campaigns.
- Quantitative Output: Luminescent strain enables daily, non-invasive bacterial burden measurement for dose-response assessment.
- Scalability: Compatible with high-containment imaging systems for longitudinal efficacy tracking across treatment groups.
Translational & Preclinical Research
- Disease Relevance: Mimics human post-operative infection timelines, enhancing translational predictability.
- Mechanistic De-risking: Allows evaluation of host-pathogen interactions and virulence factor contributions in immunocompetent hosts.
- Preclinical Continuity: Supports risk-adjusted advancement decisions by linking in vivo efficacy to quantifiable bacterial burden reduction.
Pipeline & Workflow Integration
The model fits within the discovery continuum from target validation through lead identification to preclinical efficacy testing, particularly for topical and systemic anti-infectives.
- Discovery Biology: Tests target essentiality in chronic infection phenotypes where acute clearance models fail.
- Screening: Delivers quantitative, time-resolved infection metrics enabling IC50 and MIC determinations in vivo.
- Analytics: Bioluminescence flux provides longitudinal pharmacodynamic readouts for PK/PD modeling.
- Translational Research: Connects molecular findings to clinical infection trajectories via temporal wound progression.
- Enterprise Reuse: Establishes a reusable platform for evaluating multiple antimicrobial classes against P. aeruginosa wound persistence.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity in virulence and resistance studies through chronic infection modeling.
- Operational Value: Eliminates need for immunosuppressants or biomaterials, simplifying workflow and reducing variability.
- Strategic Value: Improves go/no-go decisions by predicting clinical failure risks associated with biofilm or tolerance mechanisms.
- Portfolio Impact: Enables risk-based prioritization of candidates demonstrating durable wound infection control.
Implementation Considerations
- Requires expertise in murine wound surgery and aseptic technique.
- Dependent on bioluminescence imaging infrastructure and BSL-2 compliant handling.
- Necessitates standardization of wound size, inoculation timing, and nutritional support across sites.
- Adaptation to diabetic or immunocompromised models may require validation of infection kinetics.
- Practical limitation: Model assesses superficial wound infection; deep tissue or osteomyelitis phenotypes require alternative systems.
Biopharma FAQs
Why does delayed inoculation prevent rapid clearance in P. aeruginosa wound models?
Inoculating 24 hours post-wounding allows the provisional matrix to form, which forestalls rapid bacterial clearance or dissemination and instead establishes a stable chronic infection lasting 7–10 days without immunosuppression or foreign materials.
How does isolating the wound environment as an independent variable improve target validation?
By standardizing wound creation and controlling inoculation timing, the model isolates the pathogen-host interaction as the key variable, enabling reliable assessment of target-specific effects on bacterial persistence.
What quantitative dependent variable measurements enable efficacy assessment in this model?
Bioluminescence flux (photons/second) from the lux-expressing P. aeruginosa strain provides a quantitative, longitudinal readout of bacterial burden, correlating with CFU counts for accurate infection tracking.
Why are replication requirements critical for cross-functional collaboration in infection model adoption?
Consistent 7–10 day infection duration across replicates ensures reliability between discovery, preclinical, and translational teams, supporting standardized go/no-go criteria for therapeutic candidates.
What statistical analysis capabilities are required before implementing this model in screening cascades?
Teams must be able to analyze longitudinal bioluminescence data, calculate area under the curve, and perform group comparisons using appropriate parametric or non-parametric tests to assess treatment effects on infection trajectory.
